Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Daiichi Sankyo Co., Ltd. Stock Deutsche Boerse AG

Equities

D4S

JP3475350009

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 10:50:52 2024-04-29 EDT 		5-day change 1st Jan Change
30.24 EUR +2.88% Intraday chart for Daiichi Sankyo Co., Ltd. +9.79% +24.64%
04:27pm AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement MT
10:14am AstraZeneca makes progress with Truqap and Enhertu cancer treatments AN

Financials

Sales 2024 1,602B 10.21B 9.54B 13.96B Sales 2025 * 1,761B 11.23B 10.49B 15.35B Capitalization 9,607B 61.26B 57.24B 83.73B
Net income 2024 201B 1.28B 1.2B 1.75B Net income 2025 * 186B 1.18B 1.11B 1.62B EV / Sales 2024 5.72 x
Net cash position 2024 * 556B 3.54B 3.31B 4.84B Net cash position 2025 * 455B 2.9B 2.71B 3.97B EV / Sales 2025 * 5.2 x
P/E ratio 2024
45.6 x
P/E ratio 2025 *
49 x
Employees 17,435
Yield 2024
1.05%
Yield 2025 *
1.14%
Free-Float 97.04%
More Fundamentals * Assessed data

Chart Daiichi Sankyo Co., Ltd.

Dynamic Chart

Latest news about Daiichi Sankyo Co., Ltd.

AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement MT
AstraZeneca makes progress with Truqap and Enhertu cancer treatments AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study MT
Hipgnosis Songs Fund backs new Blackstone bid AN
Scholz pledges further support for the pharmaceutical industry DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 MT
AstraZeneca upbeat as cancer drugs underpin sales growth AN
Transcript : Daiichi Sankyo Company, Limited, 2024 Earnings Call, Apr 25, 2024
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million. CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan. CI
Middle East Tensions Dent Asian Stock Markets MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication MT
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu MT
AstraZeneca: US approval extended for Enhertu CF
More news

Latest transcript on Daiichi Sankyo Co., Ltd.

Logo Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited, 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on Daiichi Sankyo Co., Ltd.

Jefferies Adjusts Daiichi Sankyo’s Price Target to 5,600 Yen From 4,800 Yen, Keeps at Buy MT
Berenberg: AstraZeneca Set for More Lung Cancer Success After Recent Pipeline Gains MT
Japan's Nikkei slips after Fed chair signals delay in rate cut RE
Jefferies Upgrades Daiichi Sankyo to Buy From Hold, Adjusts Price Target to 4,800 Yen From 4,300 Yen MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 4,300 Yen From 3,900 Yen, Keeps at Hold MT
More recommendations

Press releases Daiichi Sankyo Co., Ltd.

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial BU
Daiichi Sankyo : Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB PU
Daiichi Sankyo : FY2023 Reference Dat PU
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours AQ
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB PU
More press releases

News in other languages on Daiichi Sankyo Co., Ltd.

Scholz sichert Pharmabranche weiter Unterstützung zu
Scholz verspricht Pharma-Branche bei Merck weitere Unterstützung
Le marché devient un peu timbré
En Direct des Marchés : Hermès, Schneider, Atos, Carrefour, Casino, Sanofi, STMicro, Meta...
Pharmabranche erwartet Aufschwung - Standort Deutschland zunehmend gefragt
More news

Quotes and Performance

1 day+2.88%
1 week+9.79%
Current month+2.05%
1 month+5.30%
3 months+13.73%
6 months+22.28%
Current year+24.64%
More quotes

Highs and lows

1 week
27.80
Extreme 27.8
30.40
1 month
26.61
Extreme 26.61
30.40
Current year
24.46
Extreme 24.46
33.13
1 year
22.35
Extreme 22.35
34.48
3 years
15.05
Extreme 15.05
34.80
5 years
14.23
Extreme 14.2333
34.80
10 years
3.72
Extreme 3.717
34.80
More quotes

Managers and Directors - Daiichi Sankyo Co., Ltd.

Managers TitleAgeSince
Sunao Manabe CEO
 Chief Executive Officer 69 07-03-31
Hiroyuki Okuzawa PSD
 President 61 17-03-31
Ken Takeshita CTO
 Chief Tech/Sci/R&D Officer - 21-03-31
Members of the board TitleAgeSince
Sawako Nohara BRD
 Director/Board Member 66 19-05-31
Kazuaki Kama BRD
 Director/Board Member 75 19-05-31
Sunao Manabe CEO
 Chief Executive Officer 69 07-03-31
More insiders

Quotes

Date Price Change Volume
24-04-29 30.4 +3.44% 180
24-04-26 29.39 +0.41% 0
24-04-25 29.27 +3.06% 135
24-04-24 28.4 +2.16% 150
24-04-23 27.8 +0.40% 65

Delayed Quote Deutsche Boerse AG, April 29, 2024 at 10:38 am

More quotes

Company Profile

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-07-30 - Q1 2024 Earnings Release (Projected)
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,010 JPY
Average target price
5,673 JPY
Spread / Average Target
+13.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.51% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.94% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.54% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.40% 332B
ABBVIE INC. Stock AbbVie Inc.
+2.58% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.72% 231B
NOVARTIS AG Stock Novartis AG
+5.15% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.12% 195B
AMGEN INC. Stock Amgen Inc.
-5.05% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock